nei THIS MONTH IN
PSYCHOPHARMACOLOGY
Browsing articles in "Bipolar Disorders"

 

FDA Grants Breakthrough Device Designation to TMS Device for Bipolar Depression
March 26, 2020   

The U.S. Food and Drug Administration has granted Breakthrough Device designation for NeuroStar® Advanced Therapy, a transmagnetic stimulation (TMS) device, for the treatment of bipolar depression. Although TMS is approved for the treatment of...
 Continue reading (Members only)
Severe Clinical Consequences of Childhood Abuse and Neglect
February 10, 2020   

l infarction, cerebrovascular disease, type 2 diabetes, asthma, cancer, and overall lowered life expectancy. In this article, the authors review the current state of research regarding the association of early childhood abuse/neglect with development of psychiatric illness, particularly mood disorders such as...
 Continue reading (Members only)
Predicting Bipolar Disorder
October 11, 2019   

The International Society of Bipolar Disorders (ISBD) task force has recently published work attempting to identify some of the precursors and prodromes that may predict eventual diagnosis of bipolar disorder...
 Continue reading
Cariprazine Now Approved for Full Spectrum of Bipolar I Disorder Symptoms
June 7, 2019   

The U.S. Food and Drug Administration has approved the supplemental new drug application for cariprazine for the treatment of depressive episodes associated with bipolar I disorder in adults. In the three studies submitted with the supplemental new drug application, including...
 Continue reading
Age and Mixed Features May Predict Next-Step Strategies for Depression Remission
May 25, 2019   

Approximately 2/3 of patients with major depressive disorder (MDD) do not achieve remission despite adequate treatment with an antidepressant. It would be of utmost benefit to clinicians to be able to predict which patients would do better with which specific next-step treatment strategies -whether it be switching to a different antidepressant, combination of two antidepressants, or augmentation with a psychotropic from another drug class -rather than relying on trial and error...
 Continue reading
Lithium Use During Pregnancy and Maternal and Infant Outcomes
July 13, 2018   

Lithium is a staple and highly effective medication for the treatment of bipolar disorder; however, past data have indicated somewhat mixed data regarding the teratogenic effects of lithium use during pregnancy...
 Continue reading
2018 APA Highlight: Immunotherapies in Schizophrenia and Bipolar Disorder
May 5, 2018   

During the 2018 American Psychiatric Association (APA) Annual Meeting, Dr. Mark Weiser discussed the latest therapies being investigated to treat inflammation in schizophrenia and bipolar disorder...
 Continue reading
FDA Warns of Serious Immune System Reaction with Lamotrigine
April 25, 2018   

FDA issues warning that lamotrigine can cause a rare but very serious reaction that excessively activates the body’s infection-fighting immune system...
 Continue reading
Updated Recommendations For Treatment of Tardive Syndrome
April 20, 2018   

The American Academy of Neurology (AAN) has released updated recommendations for treatment of tardive syndromes...
 Continue reading (Members only)
FDA Approves Lurasidone for Pediatric Bipolar Depression
March 8, 2018   

The US Food and Drug Administration (FDA) has approved lurasidone for the treatment of bipolar depression in pediatric patients (ages 10 to 17)...
 Continue reading
123
Top of Page